ArticleCancer reports (Hoboken, N.J.)2026
Prevalence and Risk Factors for Financial Toxicity Among Sarcoma Patients During and Following Treatment Across the Lifespan.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundFinancial toxicity (FT) describes the impact of cancer and treatment-related financial burden. We evaluated the prevalence and risk factors for FT among sarcoma patients.
methodsA sarcoma cohort was constructed to assess health outcomes. FT was measured via "COmprehensive Score for financial Toxicity" (COST), where lower scores indicate greater FT. COST scores were evaluated in association with patient demographics, clinical data, and psychosocial/functional domains (PROMIS-57) using multivariable linear regression. Subgroup analyses evaluated patients on- versus off-therapy.
resultsAmong 1125 participants (515 on/610 off therapy), median COST was 27.0 (IQR 18.0, 35.0), with absent, mild, moderate, and severe FT seen in 55.4%, 29.2%, 15.1%, and 0.4%, respectively. Lower FT was associated with increasing age (+1.28; 95% CI 0.86, 1.70), male sex (+1.93; 0.78, 3.08), and higher income (+0.87; 0.72, 1.01). Increased FT was associated with non-White race (-1.79; -3.41, -0.13), larger households (-0.73; -1.25, -0.22), metastatic disease (-2.36; -3.80, -0.91), and active treatment (-1.61; -2.97, -0.24). Subgroup analyses demonstrated similar results regarding age, sex, income, and metastatic disease among on-therapy and age, income, and household members among off-therapy. Eight hundred and thirty-two participants completed both the PROMIS-57 and COST. FT was associated with anxiety (-0.77; -1.45, -0.08), depression (-2.11; -2.96, -1.26), pain interference (-1.36; -2.17, -0.55), and sleep disturbance (-0.68; -1.35, -0.004).
conclusionAlmost half of participants experienced FT. Risk factors included non-White race, active therapy, larger households, and metastatic disease. Anxiety, depression, pain interference, and sleep disturbance were associated with FT. Screening for FT is needed to develop targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.